These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 32469467)
1. Late-onset Hypogonadism: Bone health. Rochira V Andrology; 2020 Nov; 8(6):1539-1550. PubMed ID: 32469467 [TBL] [Abstract][Full Text] [Related]
2. Late-onset hypogonadism: a concept comes of age. Nieschlag E Andrology; 2020 Nov; 8(6):1506-1511. PubMed ID: 31639279 [TBL] [Abstract][Full Text] [Related]
3. Critical evaluation of different available guidelines for late-onset hypogonadism. Giagulli VA; Castellana M; Lisco G; Triggiani V Andrology; 2020 Nov; 8(6):1628-1641. PubMed ID: 32593233 [TBL] [Abstract][Full Text] [Related]
5. Late-onset hypogonadism: Reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy. Sesti F; Pofi R; Minnetti M; Tenuta M; Gianfrilli D; Isidori AM Andrology; 2020 Nov; 8(6):1614-1627. PubMed ID: 32737921 [TBL] [Abstract][Full Text] [Related]
6. Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects. Antonio L; Caerels S; Jardi F; Delaunay E; Vanderschueren D Andrology; 2019 May; 7(3):302-306. PubMed ID: 30851011 [TBL] [Abstract][Full Text] [Related]
7. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807 [TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitors and selective estrogen receptor modulators: Unconventional therapies for functional hypogonadism? Awouters M; Vanderschueren D; Antonio L Andrology; 2020 Nov; 8(6):1590-1597. PubMed ID: 31696669 [TBL] [Abstract][Full Text] [Related]
9. Controversial aspects of testosterone in the regulation of sexual function in late-onset hypogonadism. Maggi M; Filippi S; Vignozzi L; Rastrelli G Andrology; 2020 Nov; 8(6):1580-1589. PubMed ID: 32248652 [TBL] [Abstract][Full Text] [Related]
10. Late-onset hypogonadism: Prostate safety. Miranda EP; Torres LO Andrology; 2020 Nov; 8(6):1606-1613. PubMed ID: 32056383 [TBL] [Abstract][Full Text] [Related]
13. Testosterone replacement therapy for late-onset hypogonadism: current trends in Korea. Ko YH; Kim JJ Asian J Androl; 2011 Jul; 13(4):563-8. PubMed ID: 21572448 [TBL] [Abstract][Full Text] [Related]
15. [Testosterone and bone: indications and limitations]. Stoll D; Puder JJ; Lamy O Rev Med Suisse; 2011 Jun; 7(299):1311-5. PubMed ID: 21793421 [TBL] [Abstract][Full Text] [Related]
16. Testosterone, bone and osteoporosis. Tuck S; Francis R Front Horm Res; 2009; 37():123-132. PubMed ID: 19011293 [TBL] [Abstract][Full Text] [Related]
17. Osteoporosis in men with hypogonadism because of ApoA-I Leu75Pro amyloidosis under long-term testosterone therapy. Facondo P; Delbarba A; Pezzaioli LC; Ferlin A; Cappelli C Andrology; 2023 Sep; 11(6):1077-1085. PubMed ID: 36624081 [TBL] [Abstract][Full Text] [Related]
19. Late-onset hypogonadism: metabolic impact. Grossmann M; Ng Tang Fui M; Cheung AS Andrology; 2020 Nov; 8(6):1519-1529. PubMed ID: 31502758 [TBL] [Abstract][Full Text] [Related]
20. Serum total estradiol, but not testosterone is associated with reduced bone mineral density (BMD) in HIV-infected men: a cross-sectional, observational study. Santi D; Madeo B; Carli F; Zona S; Brigante G; Vescini F; Guaraldi G; Rochira V Osteoporos Int; 2016 Mar; 27(3):1103-1114. PubMed ID: 26510848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]